Showing results (371-380 of 1,648) with videos related to

Sort By:
Pageof 165
Hepatology International|May 19, 2026
Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver diseaseChencheng Xie, Mohamed A Elfeki, Winston Dunn, et al.
Hepatology International|May 26, 2026
Clinical clustering identifies MASLD subtypes with distinct longitudinal cardiovascular risks and lipidomic profilesZhixin Tu, Yu Ding, Tong Yue, et al.
Hepatology International|June 12, 2026
Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinomaKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Hepatology International|July 27, 2026
GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trialsShi-Ping Sun, Chen-Xi Wang, Ming-Kai Yuan, et al.
Hepatology International|September 1, 2016
Hepatic stellate cells: fibrogenic, regenerative or both? Heterogeneity and context are keyMeena B Bansal
Hepatology International|August 8, 2026
HBV RNA, HBcrAg, and HBsAg levels at year 6 do not predict HCC risk in patients with cirrhosis on long-term entecavir therapyHung-Hsuan Pan, Tung-Hung Su, Tsung-Hui Hu, et al.
Hepatology International|August 12, 2026
Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from TürkiyeHilmi Erdem Sumbul, Ali Kirik, Selcuk Yaylaci, et al.
Hepatology International|October 13, 2026
Diverging rate and absolute burden patterns of liver cancer attributable to NASH: global evidence and China as a sentinel caseJunpeng Luo, Xiao Qi, Yandan Wang
Hepatology International|October 14, 2026
A real-world multicenter study of statins in compensated advanced chronic liver disease on hepatic decompensation and mortality outcomesCheng Han Ng, N Apoorva Sasikumar, Margaret L P Teng, et al.
Hepatology International|September 16, 2026
Coronary atherosclerosis across stages of metabolic dysfunction-associated steatotic liver disease: a VCTE-CCTA studyGediz Dogay Us, Francesco Innocenti, Ozgur Muhammet Koc, et al.
Pageof 165